Key result
Apolipoprotein C-III promotes cardiovascular disease through both triglyceride metabolism regulation and direct atherogenic effects, making it a promising therapeutic target.
Answers are grounded in this paper and cite their sources.
Apolipoprotein C-III is a multifaceted protein involved in triglyceride metabolism and atherosclerosis, presenting a target for novel therapies like antisense technology.
Apolipoprotein C-III has been referred to as an important participant in the metabolism of triglyceride-rich lipoproteins, leading to hypertriglyceridemia and thereafter cardiovascular disease. Accumulating evidence indicates that apolipoprotein C-III is a multifaceted protein which not only regulates triglyceride metabolism, but also participates in the atherosclerotic lesion formation and several other pathological processes involved in atherosclerosis. Based on data from experiments and clinical trials, some novel therapies such as antisense technology emerge.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2016) conducted a review in Cardiovascular disease. Apolipoprotein C-III targeted therapies was evaluated. Apolipoprotein C-III promotes cardiovascular disease through both triglyceride metabolism regulation and direct atherogenic effects, making it a promising therapeutic target.
Synapse has enriched 10 related papers. Consider them for comparative context: